Deliver Your News to the World

Jerini to Hold Press Conference at the European Academy of Dermatology and Venereology Congress in Rhodes, Greece


Berlin, October 5, 2006 – Jerini AG (FSE:JI4) announced today that Dr. Jochen Knolle, Chief Scientific Officer and Head of R&D at Jerini, and Dr. Adi Hoess, Chief Commercial Officer at Jerini, along with hereditary angioedema (HAE) medical specialists Dr. Werner Aberer (Graz, Austria), Dr. Marco Cicardi (Milan, Italy), and Michel Raguet (HAE patient organization in France) will hold a press conference on October 6, 2006, at 10:00 a.m. (EEST) in Rhodes, Greece. The press conference will give an overview of the genetic disease HAE and outline top line results of Jerini’s recently completed Phase III clinical trials of Icatibant in the treatment of HAE.
The press conference will be webcast live and can be accessed through the company website at A replay of the webcast will be available on the Jerini website two hours after the end of the press conference.
About Jerini AG
Jerini is a pharmaceutical company based in Berlin, Germany, focusing on the discovery, development, and commercialization of novel peptide-based drugs. The company pursues disease indications which have limited or no treatment options and has built a drug pipeline composed of its own programs, as well as others in collaboration with partners. Jerini recently reported positive Phase III clinical results of Icatibant in the subcutaneous treatment of hereditary angioedema and plans to begin filing for marketing approval year-end 2006, with product launch in 2007. Based on its technology platform, Jerini has also established several in-house development programs, which address indications within ophthalmology, oncology, and inflammatory therapeutic areas. The most advanced of these programs targets age-related macular degeneration (AMD), the leading cause of vision loss and blindness in people over the age of 55 in developed countries, and is scheduled to begin clinical testing in the first half of 2007.
ISIN: DE0006787476


This news content was configured by WebWire editorial staff. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.